Y-mAbs Therapeutics IncNASDAQ:YMAB
- LAST PRICE12.3100
- TODAY'S CHANGE (%)-0.4200 (-3.2993%)
- Bid / Lots12.0000/ 1
- Ask / Lots16.2100/ 2
- Open / Previous Close12.7300 / 12.7300
- Day Range
- 52 Week Range
- Volume384,406
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | YMAB |
|---|---|---|
| 09:32 ET | 1488 | 12.73 |
| 09:39 ET | 1143 | 12.5548 |
| 09:41 ET | 400 | 12.71 |
| 09:43 ET | 9503 | 12.88 |
| 09:45 ET | 1752 | 12.845 |
| 09:50 ET | 100 | 12.83 |
| 09:52 ET | 100 | 12.83 |
| 09:54 ET | 200 | 12.82 |
| 09:56 ET | 100 | 12.79 |
| 09:57 ET | 300 | 12.735 |
| 10:01 ET | 100 | 12.65 |
| 10:03 ET | 1134 | 12.56 |
| 10:06 ET | 100 | 12.6 |
| 10:10 ET | 100 | 12.55 |
| 10:24 ET | 100 | 12.44 |
| 10:30 ET | 300 | 12.405 |
| 10:33 ET | 100 | 12.35 |
| 10:35 ET | 522 | 12.33 |
| 10:37 ET | 1500 | 12.46 |
| 10:42 ET | 470 | 12.395 |
| 10:46 ET | 100 | 12.41 |
| 10:48 ET | 816 | 12.405 |
| 10:50 ET | 200 | 12.43 |
| 11:02 ET | 300 | 12.42 |
| 11:06 ET | 100 | 12.42 |
| 11:08 ET | 100 | 12.425 |
| 11:09 ET | 100 | 12.43 |
| 11:18 ET | 200 | 12.435 |
| 11:20 ET | 1189 | 12.36 |
| 11:24 ET | 200 | 12.33 |
| 11:31 ET | 300 | 12.31 |
| 11:33 ET | 100 | 12.3 |
| 11:38 ET | 100 | 12.325 |
| 11:42 ET | 100 | 12.3 |
| 11:49 ET | 300 | 12.29 |
| 11:51 ET | 900 | 12.34 |
| 11:56 ET | 138 | 12.33 |
| 12:00 ET | 200 | 12.33 |
| 12:05 ET | 100 | 12.29 |
| 12:07 ET | 610 | 12.275 |
| 12:09 ET | 200 | 12.28 |
| 12:12 ET | 100 | 12.28 |
| 12:14 ET | 200 | 12.285 |
| 12:16 ET | 1000 | 12.265 |
| 12:18 ET | 200 | 12.255 |
| 12:20 ET | 344 | 12.28 |
| 12:23 ET | 100 | 12.26 |
| 12:27 ET | 235 | 12.26 |
| 12:30 ET | 200 | 12.26 |
| 12:32 ET | 100 | 12.285 |
| 12:34 ET | 404 | 12.27 |
| 12:36 ET | 400 | 12.28 |
| 12:38 ET | 256003 | 12.325 |
| 12:39 ET | 200 | 12.325 |
| 12:41 ET | 1216 | 12.41 |
| 12:43 ET | 166 | 12.405 |
| 12:45 ET | 300 | 12.39 |
| 12:48 ET | 2335 | 12.39 |
| 12:50 ET | 1829 | 12.23 |
| 12:52 ET | 1200 | 12.19 |
| 12:54 ET | 616 | 12.14 |
| 01:01 ET | 1099 | 12.14 |
| 01:03 ET | 100 | 12.2 |
| 01:08 ET | 100 | 12.185 |
| 01:14 ET | 400 | 12.19 |
| 01:15 ET | 733 | 12.19 |
| 01:17 ET | 976 | 12.225 |
| 01:19 ET | 200 | 12.25 |
| 01:21 ET | 113 | 12.24 |
| 01:26 ET | 200 | 12.3 |
| 01:32 ET | 100 | 12.26 |
| 01:33 ET | 100 | 12.26 |
| 01:39 ET | 700 | 12.305 |
| 01:46 ET | 400 | 12.26 |
| 01:50 ET | 250 | 12.24 |
| 02:00 ET | 287 | 12.22 |
| 02:02 ET | 100 | 12.22 |
| 02:04 ET | 100 | 12.2 |
| 02:06 ET | 100 | 12.2 |
| 02:13 ET | 100 | 12.19 |
| 02:22 ET | 100 | 12.18 |
| 02:24 ET | 132 | 12.19 |
| 02:27 ET | 700 | 12.17 |
| 02:29 ET | 100 | 12.165 |
| 02:31 ET | 300 | 12.13 |
| 02:33 ET | 1689 | 12.22 |
| 02:36 ET | 1307 | 12.245 |
| 02:42 ET | 736 | 12.245 |
| 02:44 ET | 300 | 12.26 |
| 02:45 ET | 200 | 12.25 |
| 02:51 ET | 224 | 12.25 |
| 02:54 ET | 478 | 12.295 |
| 02:56 ET | 100 | 12.295 |
| 02:58 ET | 200 | 12.25 |
| 03:00 ET | 600 | 12.245 |
| 03:02 ET | 500 | 12.25 |
| 03:05 ET | 1482 | 12.29 |
| 03:14 ET | 198 | 12.3 |
| 03:20 ET | 193 | 12.3001 |
| 03:21 ET | 300 | 12.315 |
| 03:25 ET | 700 | 12.34 |
| 03:32 ET | 355 | 12.32 |
| 03:38 ET | 100 | 12.31 |
| 03:39 ET | 300 | 12.33 |
| 03:45 ET | 1529 | 12.3 |
| 03:48 ET | 200 | 12.31 |
| 03:50 ET | 900 | 12.325 |
| 03:52 ET | 487 | 12.3 |
| 03:54 ET | 780 | 12.26 |
| 03:56 ET | 2773 | 12.28 |
| 03:57 ET | 1166 | 12.26 |
| 03:59 ET | 20182 | 12.31 |
Yesterday
Press Release: Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer, from 7:05AM ET on Wednesday Jun 05, 2024 by Dow Jones
7:05AM ET on Wednesday Jun 05, 2024 by Dow JonesY-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer, from 7:05AM ET on Wednesday Jun 05, 2024 by Dow Jones
7:05AM ET on Wednesday Jun 05, 2024 by Dow Jones
Jun 1, 2024
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting, from 8:15AM ET on Saturday Jun 01, 2024 by Dow Jones
8:15AM ET on Saturday Jun 01, 2024 by Dow JonesY-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting, from 8:05AM ET on Saturday Jun 01, 2024 by Dow Jones
8:05AM ET on Saturday Jun 01, 2024 by Dow Jones
May 8, 2024
DJ Y-mAbs Therapeutics Down Over 17%, on Pace for Largest Percent Decrease Since October 2022 -- Data Talk, from 1:15PM ET on Wednesday May 08, 2024 by Dow Jones
1:15PM ET on Wednesday May 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Y-mAbs Therapeutics Inc | 531.0M | -24.8x | --- |
Urogen Pharma Ltd | 480.5M | -3.9x | --- |
Zymeworks Inc | 599.6M | -5.1x | --- |
Alector Inc | 474.2M | -3.1x | --- |
Editas Medicine Inc | 427.6M | -2.6x | --- |
SAGE Therapeutics Inc | 668.6M | -1.3x | --- |
Company Information
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Contact Information
- Headquarters
- 230 PARK AVENUE, SUITE 3350NEW YORK, NY, United States 10169
- Phone
- 212-847-9841
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- James Healy
- President, Chief Executive Officer, Director
- Michael Rossi
- Vice Chairman of the Board, Chief Business Officer
- Thomas Gad
- Chief Financial Officer, Executive Vice President, Treasurer, Secretary
- Bo Kruse
- Chief Operating Officer, Senior Vice President
- Joris Wilms
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $531.0M |
|---|---|
Revenue (TTM) | $84.5M |
Shares Outstanding | 43.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.69 |
EPS | $-0.50 |
Book Value | $2.31 |
P/E Ratio | -24.8x |
Price/Sales (TTM) | 6.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -29.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
